Reviews on Recent Clinical Trials

ISSN: 1574-8871

Reviews on Recent Clinical Trials
Volume 4, Number 1, January 2009

Contents


The Role of Capecitabine in the Management of Tumors of the Digestive System Pp. 1-11
Constantine Gennatas, Vasiliki Michalaki and Spyridon Gennatas
[Abstract] [Full Text Article] [PMID: 19149458 PubMed - indexed for MEDLINE]


Molecular Pathology of Sarcomas Pp. 12-26
Daniel Osuna and Enrique de Álava
[Abstract] [Full Text Article] [PMID: 19149459 PubMed - indexed for MEDLINE]


Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature Pp. 27-33
Davide Tassinari, Federica Carloni, Carlotta Santelmo, Emiliano Tamburini, Luigi Lazzari Agli, Paola Tombesi and Sergio Sartori
[Abstract] [Full Text Article] [PMID: 19149460 PubMed - indexed for MEDLINE]


TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges Pp. 34-41
Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder Chhabra and Chunhai Hao
[Abstract] [Full Text Article] [PMID: 19149461 PubMed - indexed for MEDLINE]


A Literature Review of the Recent Radiotherapy Clinical Trials in Pediatric Brain Tumors Pp. 42-55
Anna Skowronska-Gardas
[Abstract] [Full Text Article] [PMID: 19149462 PubMed - indexed for MEDLINE]


Treatment of Colorectal Liver Metastases: A Review Pp. 56-62
M. Van den Eynde and A. Hendlisz
[Abstract] [Full Text Article] [PMID: 19149463 PubMed - indexed for MEDLINE]


Recent Clinical Aspects of Eating Disorders Pp. 63-69
Anna Capasso, Claudio Petrella and Walter Milano
[Abstract] [Full Text Article] [PMID: 19149464 PubMed - indexed for MEDLINE]




Abstracts


[Back to top] [PMID: 19149458 PubMed - indexed for MEDLINE]
The Role of Capecitabine in the Management of Tumors of the Digestive System
Constantine Gennatas, Vasiliki Michalaki and Spyridon Gennatas

[Full Text Article]

Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse–effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant English-language literature was identified through searches of NCI, PubMed, ASCO.org and ESMO, ECCO meetings proceedings.


[Back to top] [PMID: 19149459 PubMed - indexed for MEDLINE]
Molecular Pathology of Sarcomas
Daniel Osuna and Enrique de Álava

[Full Text Article]

Bone and soft tissue sarcomas are an infrequent group of tumours with a prevalence of 4 in 100000 people/year. Sarcomas, such as synovial sarcoma, Ewing’s sarcoma and osteosarcoma, are more usual in adolescents or in young adults. Neoplasias such as leiomyosarcoma or liposarcoma are more frequent in patients over 55 years. One relevant topic is related to sarcomagenesis elucidation, a key for discovering the early molecular mechanisms involved in the development of sarcomas as well as the identification of reliable molecular markers and possible therapeutic targets. Today, it is known that the cellular context contributes to the phenotype. Analysis of gene expression profiling of human sarcomas revealed tightly clustered groups and could denote the existence of common signalling pathways for each branch. From the molecular point of view, these neoplasias are grouped into two main types: (a) sarcomas showing specific genetic alterations and relatively simple karyotypes, and translocations which originate gene fusions (e.g., EWS-FLI1 in Ewing’s sarcoma); or specific genetic mutations (e.g., c-kit in the gastrointestinal stromal tumour), and (b) sarcomas showing unspecific gene alterations and very complex karyotypes, and very numerous gains and losses. This review points out the clinical projection of sarcomagenesis elucidation and knowledge of diverse types of molecular alterations.


[Back to top] [PMID: 19149460 PubMed - indexed for MEDLINE]
Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature
Davide Tassinari, Federica Carloni, Carlotta Santelmo, Emiliano Tamburini, Luigi Lazzari Agli, Paola Tombesi and Sergio Sartori

[Full Text Article]

In the last 10 years the medical approach to platinum-resistant Non Small Cell Lung Cancer (NSCLC) has radically changed, passing from a lack of evidence of any primary treatment against the tumor, to the identification of chemo-therapy or EGFR inhibitors as the gold standard for clinical practice. Eight randomized clinical trials support the evidence of efficacy of second-line treatments against NSCLC, and docetaxel, pemetrexed and erlotinib are the most effective options for clinical practice. However, many aspects remain still undefined:

• Can a treatment with docetaxel, pemetrexed or erlotinib be considered the gold standard for all patients with platinum-resistant NSCLC, and consequently should all patients be treated with at least one of these options?

• Are the benefits enough to justify the side effects observed with these chemotherapeutic options?

• Can a schedule be preferred to the others for either efficacy or safety profile?

• Can the new EGFR inhibitors be considered an innovation in the treatment of platinum-resistant NSCLC, and should they be used in all patients with platinum-resistant NSCLC?

A systematic review of randomized clinical trials and a critical analysis of the results were performed with the aim to clarify the real meaning of medical treatments in advanced, platinum-resistant NSCLC.


[Back to top] [PMID: 19149461 PubMed - indexed for MEDLINE]
TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Anita C. Bellail, Ling Qi, Patrick Mulligan, Vaninder Chhabra and Chunhai Hao

[Full Text Article]

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is normally expressed in the human immune system and plays a critical role in antitumor immunity. TRAIL interacts with the death receptors, DR4 and DR5, and activates intracellular apoptotic pathway in cancer cells. This discovery has resulted in a rapid development of cancer therapeutic agents that can activate this apoptotic pathway. These therapeutic agents include recombinant human TRAIL (rhTRAIL) and its agonistic monoclonal antibody (MAb) against DR4 and DR5. Phase I trials have established the safety and tolerability of these TRAIL agonists in patients. Phase II trials are currently evaluating the therapeutic efficacy of TRAIL agonists as single agents or in combination with established cancer therapeutics. This review outlines the advances and the challenges in the development of these TRAIL agonists as effective clinical cancer therapeutics.


[Back to top] [PMID: 19149462 PubMed - indexed for MEDLINE]
A Literature Review of the Recent Radiotherapy Clinical Trials in Pediatric Brain Tumors
Anna Skowronska-Gardas

[Full Text Article]

Primary central nervous system neoplasms are the second malignancy in children following leukemia. Despite developments in neurosurgery and new drugs in chemotherapy, irradiation is an essential part of the management in most of pediatric brain tumors. A good treatment strategy should consider not only survival but also the quality of life.

The new approach of radiotherapy and importance of new drugs in combined treatment are recently considered. This article summarizes the recent clinical trials conducted in pediatric brain tumors management. Results of randomized study of pre-irradiation chemotherapy versus radiotherapy alone for medulloblastoma were presented by SIOP/UKCCSG PNET-3.

The French M-SFOP 98 protocol considered hyper-fractionated radiotherapy with reduced boost volume, without chemotherapy and estimated impact on early relapses and intellectual function. The influence of radiotherapy quality on survival in high-risk medulloblastoma patients was evaluated in POG Trial 9031. In the treatment of low-grade glioma in children the effectiveness of novel combination chemotherapy was considered. Role of new drugs as temozolamid, topotecan and RMP-7 was investigated in pediatric high grade glioma and brain stem tumors. Impact of combined treatment on outcome of intracranial germ-cell tumors was investigated as well.


[Back to top] [PMID: 19149463 PubMed - indexed for MEDLINE]
Treatment of Colorectal Liver Metastases: A Review
M. Van den Eynde and A. Hendlisz

[Full Text Article]

Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the management of advanced disease with chemotherapy, liver resection remains the only hope for cure for patients with colorectal liver metastases. Approximately 15% of patients with stage IV CRC referred to specialist centers have metastatic liver disease deemed to be resectable at presentation. Over the last five years, combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin and, more recently, integrating targeted monoclonal antibodies, have been shown to downsize the tumour burden to an extent that sometimes allows initially unresectable metastases to be excised. Five-year survival rates following liver resection range between 25% and 55% compared with 0% and 5% for non-operated patients. Beyond liver resection, the rationale for “pseudo-adjuvant” chemotherapy lacks scientific evidence, despite some promising data. However, perioperative chemotherapy for resectable lesions is gaining ground in current practice. In this article we review the state of the art treatment for CRC liver metastases and, considering the results of recent trials, try to determine the appropriate role of chemotherapy.


[Back to top] [PMID: 19149464 PubMed - indexed for MEDLINE]
Recent Clinical Aspects of Eating Disorders
Anna Capasso, Claudio Petrella and Walter Milano

[Full Text Article]

This review focuses on Eating Disorders (ED), the role played by neurotransmitters and peptides in ED phenomena as well as the drugs used in the treatment of these diseases. For ED, we mean a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the inges-tion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion, thus, causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reup-take inhibitors and tricyclic antidepressants. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.